Last reviewed · How we verify
anti-osteoporotic medication
At a glance
| Generic name | anti-osteoporotic medication |
|---|---|
| Also known as | all available anti-osteoporotic medication |
| Sponsor | Hellenic Society for the Study of Bone Metabolism |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease (PHASE4)
- Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder (PHASE2)
- Post-fracture Medication and Mortality
- Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy
- Prediction and Secondary Prevention of Fractures
- Secondary Prevention of Osteoporotic Fractures: a Multiple Center Fracture Liaison Service in Greece
- Metabolic Therapy in Patients With Osteoporosis After Hip Fracture by an Orthopedic-rehabilitation-metabolic Team (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: